Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Merck
Mallinckrodt
McKesson
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202097

See Plans and Pricing

« Back to Dashboard

NDA 202097 describes FENTANYL-75, which is a drug marketed by 3m Drug Delivery, Actavis Labs Ut Inc, Aveva, Lavipharm Labs, Mayne Pharma, Mylan Technologies, Noven, and Specgx Llc, and is included in eight NDAs. It is available from eight suppliers. Additional details are available on the FENTANYL-75 profile page.

The generic ingredient in FENTANYL-75 is fentanyl. There are thirty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the fentanyl profile page.
Summary for 202097
Tradename:FENTANYL-75
Applicant:3m Drug Delivery
Ingredient:fentanyl
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 202097
Mechanism of ActionFull Opioid Agonists
Medical Subject Heading (MeSH) Categories for 202097
Suppliers and Packaging for NDA: 202097
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FENTANYL-100 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 202097 ANDA Alvogen 47781-423 47781-423-47 1 POUCH in 1 CARTON (47781-423-47) > 5 PATCH in 1 POUCH
FENTANYL-100 fentanyl FILM, EXTENDED RELEASE;TRANSDERMAL 202097 ANDA Alvogen 47781-424 47781-424-47 1 POUCH in 1 CARTON (47781-424-47) > 5 PATCH in 1 POUCH

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength12.5MCG/HR
Approval Date:Nov 4, 2016TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength25MCG/HR
Approval Date:Nov 4, 2016TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:FILM, EXTENDED RELEASE;TRANSDERMALStrength50MCG/HR
Approval Date:Nov 4, 2016TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Colorcon
Baxter
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.